Loading
Valink Therapeutics
Valink designs antibody-drug conjugates that grab two targets at once, aimed at solid tumours that immunotherapy does not reach.
Overview
Valink Therapeutics discovers next-generation antibody-based therapeutics by combining multiple modifications, bispecificity, multivalency and payload conjugation, in a single discovery workflow, generating bispecific antibody-drug conjugates from known tumour targets with new mechanisms of action. Its stated focus is solid tumours poorly served by immunotherapy. Programmes are preclinical as far as public sources show; no sourced financing rounds are recorded.
Headquarters
Boston, MA, US
Funding
All startupsStartupYC W21
Investors
Type
Stage
Startup · Y Combinator Winter 2021
Website
Connected
4Similar pages
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator and the tag yc.
- CompanyTriomics
Shares Y Combinator and the tag yc.
fronts
technologies
companies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
valinktx.com · 1
ycombinator.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/